Latest CancerVax Stories

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

2009-04-02 06:00:00

BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first clinical trial application (CTA) in Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million Euro (US$ 2.0 million) from Nycomed for the achievement of this milestone. Under a 2007...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

2009-03-26 06:00:00

BETHESDA, Md., March 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the Future Leaders in the Biotech Industry conference at the Millennium Broadway Hotel & Conference Center in New York City on Thursday, April 2, 2009. A simultaneous webcast of the...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

2009-03-23 06:00:00

Randomized, Controlled, Multicenter Trial Will Test Ability of Adecatumumab to Prolong Disease Free Survival in High Risk Patients with Liver Metastases BETHESDA, Md., March 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the commencement of a randomized, controlled phase 2 trial of its human anti-EpCAM IgG1 antibody...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

2009-03-19 06:00:00

Appointments Strengthen Expertise in Immunotherapy of Cancer BETHESDA, Md., March 19 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the the appointment of Sir Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel. Other members of the company's advisory panel include professors Richard Flavell (Yale University),...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

2009-03-16 06:00:00

BETHESDA, Md., March 16 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of six abstracts for poster presentations at the 100th annual meeting of AACR taking place from April 20-24, 2009, in Denver, Colorado. The following posters will be presented: Lutterbuese, R. et al. (2009). Highly efficient lysis of KRAS- and...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

2009-03-12 06:00:00

BETHESDA, Md., March 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it is regaining from its partner MedImmune the rights in North America to its most advanced BiTE antibody candidate, blinatumomab, also known as MT103. In Europe, Micromet is conducting a phase 2 clinical trial with blinatumomab for the treatment of...

Micromet to Present at the Cowen Health Care Conference on March 17, 2009

2009-03-06 11:30:00

BETHESDA, Md., March 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts on Tuesday, March 17, 2009. A simultaneous webcast of the presentation will be available on the...

Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results on March 12, 2009

2009-02-27 06:00:00

BETHESDA, Md., Feb. 27 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that that it will host a conference call and audio webcast on Thursday, March 12, 2009, at 9:00 am Eastern Time (2:00 pm Central European Time) to discuss its financial results for the fourth quarter and the full year of 2008. Micromet anticipates releasing its...

Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors

2009-02-23 06:00:00

BETHESDA, Md., Feb. 23 /PRNewswire/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Kapil Dhingra has joined its Board of Directors, effective as of February 18, 2009. As a result of Dr. Dhingra's appointment, the Board is now comprised of nine members. Dr. Dhingra has been active in oncology clinical research for over 20 years. During his...

Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference

2009-02-13 09:55:00

BETHESDA, Md., Feb. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced that its Chief Financial Officer, Buck Phillips, will present at the ROTH 21st Annual Orange County Growth Stock Conference at the Ritz-Carlton Laguna Niguel on Wednesday, February 18, 2009. Forum: The ROTH 21st Annual Orange County Growth Stock Conference Date: Wednesday, February 18, 2009 Time: 4:30 pm Pacific Time Place: The Ritz-Carlton Laguna Niguel One...